-$1.39 Earnings Per Share Expected for Adamas Pharmaceuticals Inc (ADMS) This Quarter

Analysts expect Adamas Pharmaceuticals Inc (NASDAQ:ADMS) to report earnings of ($1.39) per share for the current fiscal quarter, Zacks reports. Five analysts have made estimates for Adamas Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($1.19) and the lowest estimate coming in at ($1.58). Adamas Pharmaceuticals posted earnings per share of ($1.27) in the same quarter last year, which indicates a negative year over year growth rate of 9.4%. The company is scheduled to issue its next earnings report on Thursday, February 28th.

According to Zacks, analysts expect that Adamas Pharmaceuticals will report full-year earnings of ($5.23) per share for the current fiscal year, with EPS estimates ranging from ($5.52) to ($5.01). For the next fiscal year, analysts anticipate that the business will report earnings of ($3.87) per share, with EPS estimates ranging from ($4.31) to ($2.89). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow Adamas Pharmaceuticals.

Adamas Pharmaceuticals (NASDAQ:ADMS) last posted its quarterly earnings data on Thursday, November 1st. The specialty pharmaceutical company reported ($1.22) EPS for the quarter, beating analysts’ consensus estimates of ($1.34) by $0.12. The business had revenue of $10.61 million for the quarter, compared to analyst estimates of $10.10 million. Adamas Pharmaceuticals had a negative return on equity of 106.74% and a negative net margin of 617.27%.

A number of research firms recently commented on ADMS. BidaskClub lowered Adamas Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Wednesday, August 1st. Leerink Swann began coverage on Adamas Pharmaceuticals in a research note on Monday, November 12th. They set an “outperform” rating and a $20.00 price objective on the stock. Zacks Investment Research lowered Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, October 8th. Cowen set a $30.00 price objective on Adamas Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, November 1st. Finally, Bank of America lowered Adamas Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $36.00 to $25.00 in a research note on Friday, October 5th. One analyst has rated the stock with a sell rating, four have given a hold rating and eight have given a buy rating to the company’s stock. Adamas Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $32.13.

ADMS opened at $10.51 on Friday. The company has a current ratio of 8.95, a quick ratio of 8.74 and a debt-to-equity ratio of 1.01. The firm has a market cap of $270.08 million, a P/E ratio of -2.65 and a beta of 1.53. Adamas Pharmaceuticals has a 52 week low of $9.69 and a 52 week high of $44.00.

In other Adamas Pharmaceuticals news, CEO Gregory T. Went purchased 3,850 shares of the firm’s stock in a transaction on Wednesday, November 7th. The shares were purchased at an average cost of $12.98 per share, with a total value of $49,973.00. Following the purchase, the chief executive officer now owns 182,610 shares in the company, valued at $2,370,277.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Alfred G. Merriweather sold 1,665 shares of the firm’s stock in a transaction dated Friday, September 21st. The stock was sold at an average price of $19.18, for a total value of $31,934.70. Following the completion of the sale, the chief financial officer now directly owns 25,460 shares in the company, valued at $488,322.80. The disclosure for this sale can be found here. 24.60% of the stock is currently owned by company insiders.

A number of large investors have recently modified their holdings of the business. California State Teachers Retirement System raised its holdings in shares of Adamas Pharmaceuticals by 11.2% in the 1st quarter. California State Teachers Retirement System now owns 26,179 shares of the specialty pharmaceutical company’s stock worth $626,000 after purchasing an additional 2,645 shares during the period. Allianz Asset Management GmbH raised its holdings in shares of Adamas Pharmaceuticals by 4.7% in the 1st quarter. Allianz Asset Management GmbH now owns 55,594 shares of the specialty pharmaceutical company’s stock worth $1,329,000 after purchasing an additional 2,513 shares during the period. Emerald Advisers Inc. PA raised its holdings in shares of Adamas Pharmaceuticals by 2.2% in the 2nd quarter. Emerald Advisers Inc. PA now owns 639,934 shares of the specialty pharmaceutical company’s stock worth $16,529,000 after purchasing an additional 13,821 shares during the period. Emerald Mutual Fund Advisers Trust raised its holdings in shares of Adamas Pharmaceuticals by 3.4% in the 2nd quarter. Emerald Mutual Fund Advisers Trust now owns 550,354 shares of the specialty pharmaceutical company’s stock worth $14,216,000 after purchasing an additional 17,877 shares during the period. Finally, Kornitzer Capital Management Inc. KS raised its holdings in shares of Adamas Pharmaceuticals by 81.9% in the 2nd quarter. Kornitzer Capital Management Inc. KS now owns 318,890 shares of the specialty pharmaceutical company’s stock worth $8,237,000 after purchasing an additional 143,535 shares during the period. 91.84% of the stock is currently owned by hedge funds and other institutional investors.

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its partnered approved/commercial products include Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease.

Featured Article: How can you know how many shares are floating?

Get a free copy of the Zacks research report on Adamas Pharmaceuticals (ADMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply